Geopolitical stress spotlights Serbia’s dependence on imported medicines

Geopolitical instability is forcing investors and policymakers to look beyond the familiar focus on energy security in Serbia. A less visible but strategically important vulnerability is coming into sharper view: the country’s heavy reliance on imported pharmaceuticals, medical devices and related inputs at a scale that outstrips local production.

A large import footprint with a persistent deficit

The pharmaceutical sector has become Serbia’s second-largest component of imports after oil. The trade deficit in the sector exceeds €1.16 billion, and the imbalance has largely stayed out of public debate despite mounting global concerns—particularly around Middle East-related tensions—that can affect supply chains and transport.

Economically, the dependency is structural rather than cyclical. Serbia imports medicines, medical equipment and raw materials far beyond what domestic capacity can produce. Annual imports of medicines, medical equipment and supplements exceed €1.9 billion, while exports are about €739.6 million, leaving a persistent and widening gap.

Industry restructuring reduced strategic autonomy

At the heart of this dependence is how Serbia’s pharmaceutical industry has changed over the past two decades. Large domestic producers such as Galenika and Jugoremedija have been largely privatized or diminished, with ownership and control shifting toward multinational companies. Economists argue this has reduced domestic strategic autonomy in a sector that is both profitable and critical for public health.

Today, production depth remains limited. While 24 companies are involved in some form of pharmaceutical production, only seven facilities carry out full manufacturing. Many others focus on packaging or partial processing—meaning even domestically produced medicines often rely on imported active pharmaceutical ingredients and intermediates.

Upstream concentration turns distant shocks into local risk

Global supply-chain structure compounds the problem. Over time, production of key chemical compounds and active ingredients has shifted toward large-scale hubs in China, India and South Korea. That upstream concentration affects not only Serbia but also major Western markets.

In this system, geopolitical shocks do not need to target pharmaceutical production directly to cause disruption. Instead, they can operate through indirect channels—especially energy and logistics—by affecting oil supply routes or transport corridors. The result can be a “domino effect” across global supply chains.

For Serbia, the link is particularly acute because while pharmaceuticals themselves are not tied directly to energy markets, the logistics infrastructure that supports supply—shipping routes, air freight capacity and fuel costs—is highly sensitive to geopolitical tensions. Disruptions can translate into delayed deliveries, higher costs or temporary shortages.

Short-term buffers exist; longer-term resilience looks weaker

Industry experts say immediate risks remain contained. Companies typically hold inventory buffers covering several months of production, and many raw materials are transported by air rather than sea, which reduces exposure to maritime disruptions. In addition, key supply regions are geographically distant from current conflict zones, adding short-term resilience.

The longer-term outlook is less stable because Serbia’s dependency is both external and geographically concentrated. Imports come heavily from Hungary, Switzerland, Germany, Slovenia and France, while exports go to a broader but less economically significant set of markets—reinforcing Serbia’s position as a net importer within Europe’s pharmaceutical ecosystem.

Limited domestic product coverage underscores substitution constraints

The structure of the domestic market further highlights the imbalance. Of more than 56,000 registered medical products available in Serbia, only about 1,300 are domestically produced—evidence of limited local manufacturing scope.

Even where Serbia shows relative strength—such as dietary supplements—the trade balance improves only marginally: imports and exports are nearly equal in value. That pattern suggests the broader pharmaceutical ecosystem remains anchored externally with limited ability to substitute imports if disruption persists.

From efficiency to resilience: policy debate shifts

Taken together, these factors point to systemic exposure rather than a temporary mismatch between demand and supply. In a prolonged geopolitical crisis scenario for Serbia, risks could compound through higher import costs tied to energy price spikes, logistical bottlenecks that affect delivery times, and intensified competition for limited global supplies—particularly if larger markets prioritize domestic needs.

This environment is pushing policy thinking away from pure efficiency toward resilience. Full self-sufficiency in pharmaceuticals may be neither feasible nor economically rational for a small market; however, erosion of domestic production capacity narrows strategic options. Rebuilding selected segments—especially generic drug production or critical medical supplies—is increasingly framed as less an industrial-policy question than one of national security.

What is emerging is a broader redefinition of economic vulnerability: just as energy security has moved into central policy frameworks across Europe, “pharmaceutical security” is increasingly being treated as part of the same category. For Serbia, the intersection of energy-linked logistics risk with health supply dependence creates compounded exposure that becomes most visible precisely when geopolitical stress rises.